Literature DB >> 16267008

Focal adhesion kinase promotes the aggressive melanoma phenotype.

Angela R Hess1, Lynne-Marie Postovit, Naira V Margaryan, Elisabeth A Seftor, Galen B Schneider, Richard E B Seftor, Brian J Nickoloff, Mary J C Hendrix.   

Abstract

Malignant melanoma continues to remain a significant health threat, with death often occurring as a result of metastasis. The metastatic phenotype typically is characterized by augmented tumor cell invasion and migration in addition to tumor cell plasticity as shown by vasculogenic mimicry. Therefore, understanding the molecular mechanisms that promote an aggressive phenotype is essential to predicting the likelihood of metastasis at a stage when intervention may be possible. This study focuses on the role of focal adhesion kinase (FAK), a cytoplasmic tyrosine kinase important for many cellular processes, including cell survival, invasion, and migration. We found FAK to be phosphorylated on its key tyrosine residues, Tyr397 and Tyr576, in only aggressive uveal and cutaneous melanoma cells, which correlates with their increased invasion, migration, and vasculogenic mimicry plasticity. Additionally, we confirmed the presence of FAK phosphorylated on Tyr397 and Tyr576 in both cutaneous and uveal melanoma tumors in situ. Examination of a functional role for FAK in aggressive melanoma revealed that disruption of FAK-mediated signal transduction pathways, through the expression of FAK-related nonkinase (FRNK), results in a decrease in melanoma cell invasion, migration, and inhibition of vasculogenic mimicry. Moreover, we found that FRNK expression resulted in a down-regulation of Erk1/2 phosphorylation resulting in a decrease in urokinase activity. Collectively, these data suggest a new mechanism involved in promoting the aggressive melanoma phenotype through FAK-mediated signal transduction pathways, thus providing new insights into possible therapeutic intervention strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16267008     DOI: 10.1158/0008-5472.CAN-05-2172

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  53 in total

1.  The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells.

Authors:  Maithao N Le; Joseph L-K Chan; Stephen A Rosenberg; Adam S Nabatian; Kim T Merrigan; Karine A Cohen-Solal; James S Goydos
Journal:  J Invest Dermatol       Date:  2010-05-27       Impact factor: 8.551

Review 2.  Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications.

Authors:  Balázs Döme; Mary J C Hendrix; Sándor Paku; József Tóvári; József Tímár
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

3.  Effects of microRNA-708 on Epithelial-Mesenchymal Transition, Cell Proliferation and Apoptosis in Melanoma Cells by Targeting LEF1 through the Wnt Signaling Pathway.

Authors:  Xiao-Fei Song; Qi-Hua Wang; Ran Huo
Journal:  Pathol Oncol Res       Date:  2017-11-14       Impact factor: 3.201

4.  The influence of different microenvironments on melanoma invasiveness and microcirculation patterns: an animal experiment study in the mouse model.

Authors:  Baocun Sun; Shiwu Zhang; Danfang Zhang; Yanjun Gu; Wenchao Zhang; Xiulan Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2007-06-16       Impact factor: 4.553

5.  A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells.

Authors:  Elena Kurenova; Deniz Ucar; Jianqun Liao; Michael Yemma; Priyanka Gogate; Wiam Bshara; Ulas Sunar; Mukund Seshadri; Steven N Hochwald; William G Cance
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

6.  Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry.

Authors:  Alexandra A Mourad-Zeidan; Vladislava O Melnikova; Hua Wang; Avraham Raz; Menashe Bar-Eli
Journal:  Am J Pathol       Date:  2008-11-06       Impact factor: 4.307

7.  Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical intervention.

Authors:  Luigi Strizzi; Lynne-Marie Postovit; Naira V Margaryan; Alina Lipavsky; Jules Gadiot; Christian Blank; Richard Eb Seftor; Elisabeth A Seftor; Mary Jc Hendrix
Journal:  Expert Rev Dermatol       Date:  2009

8.  Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma.

Authors:  Ha Linh Vu; Andrew E Aplin
Journal:  Mol Cancer Res       Date:  2014-06-24       Impact factor: 5.852

9.  Overexpression of carcinoma and embryonic cytotrophoblast cell-specific Mig-7 induces invasion and vessel-like structure formation.

Authors:  Aaron P Petty; Kiera L Garman; Virginia D Winn; Celee M Spidel; J Suzanne Lindsey
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

Review 10.  Tumour vascularization: sprouting angiogenesis and beyond.

Authors:  Femke Hillen; Arjan W Griffioen
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.